{"id":44830,"date":"2025-10-28T15:32:53","date_gmt":"2025-10-28T07:32:53","guid":{"rendered":"https:\/\/flcube.com\/?p=44830"},"modified":"2025-10-28T15:32:55","modified_gmt":"2025-10-28T07:32:55","slug":"eisai-and-merck-present-5%e2%80%91year-survival-data-for-lenvatinib%e2%80%91pembrolizumab-in-advanced-endometrial-carcinoma-at-esmo-2025","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=44830","title":{"rendered":"Eisai and Merck Present 5\u2011Year Survival Data for Lenvatinib\u2011Pembrolizumab in Advanced Endometrial Carcinoma at ESMO 2025"},"content":{"rendered":"\n<p>At the European Society for Medical Oncology (ESMO) 2025 Congress, Eisai (<a href=\"https:\/\/www.google.com\/finance\/quote\/4523:TYO\">TYO: 4523<\/a>) and Merck, Sharp &amp; Dohme Inc. (MSD; <a href=\"https:\/\/www.google.com\/finance\/quote\/MRK:NYSE\">NYSE: MRK<\/a>) unveiled compelling long\u2011term follow\u2011up data from the Phase\u202fIII 309\/KEYNOTE\u2011775 trial. The combination of Eisai\u2019s oral multitargeted tyrosine\u2011kinase inhibitor <strong>lenvatinib<\/strong> and MSD\u2019s anti\u2011PD\u20111 antibody <strong>Pembrolizumab (Keytruda)<\/strong> demonstrated sustained overall survival (OS) benefits over conventional chemotherapy in patients with advanced endometrial carcinoma who had progressed after at least one platinum\u2011based regimen.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-key-findings\"><strong>Key Findings<\/strong><\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Population<\/th><th>5\u2011Year OS (Len\u2011Pemb)<\/th><th>5\u2011Year OS (Chemo)<\/th><\/tr><\/thead><tbody><tr><td>All\u2011study cohort<\/td><td><strong>16.7\u202f%<\/strong><\/td><td><strong>7.3\u202f%<\/strong><\/td><\/tr><tr><td>Mismatch\u2011repair proficient (pMMR)<\/td><td><strong>19.9\u202f%<\/strong><\/td><td><strong>7.7\u202f%<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Consistent Benefit<\/strong> \u2013 The pMMR subgroup mirrors the overall cohort, underscoring the treatment\u2019s efficacy irrespective of mismatch\u2011repair status.<\/li>\n\n\n\n<li><strong>Survival Gap<\/strong> \u2013 The 9\u2011percentage\u2011point advantage over chemotherapy translates into a clinically meaningful extension of life for a historically difficult\u2011to\u2011treat population.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-implications\"><strong>Clinical Implications<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First\u2011Line Option<\/strong> \u2013 The data support lenvatinib\u2011Pembrolizumab as a durable alternative to single\u2011agent chemotherapy for platinum\u2011refractory, advanced endometrial cancer.<\/li>\n\n\n\n<li><strong>Regulatory Momentum<\/strong> \u2013 These results may influence labeling decisions and reimbursement discussions across Europe and beyond.<\/li>\n\n\n\n<li><strong>Future Research<\/strong> \u2013 Ongoing trials are exploring biomarker\u2011driven sequencing and combination strategies to further improve outcomes.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-forward-looking-statements\">Forward\u2011Looking Statements<\/h3>\n\n\n\n<p>This release contains forward\u2011looking statements that involve risks and uncertainties. Actual results may differ materially.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>At the European Society for Medical Oncology (ESMO) 2025 Congress, Eisai (TYO: 4523) and Merck,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":44837,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[106,16,17,29,350,2675,176,903,18,33,1151],"class_list":["post-44830","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-academic-conference","tag-cancer","tag-clinical-trial-results","tag-combination-therapy","tag-eisai","tag-merck-sharp-dohme","tag-msd","tag-nyse-mrk","tag-pd-1-l1","tag-tkis-egfr-vegf-btk-etc","tag-tyo-4523"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Eisai and Merck Present 5\u2011Year Survival Data for Lenvatinib\u2011Pembrolizumab in Advanced Endometrial Carcinoma at ESMO 2025 - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"At the European Society for Medical Oncology (ESMO) 2025 Congress, Eisai (TYO: 4523) and Merck, Sharp &amp; Dohme Inc. (MSD; NYSE: MRK) unveiled compelling long\u2011term follow\u2011up data from the Phase\u202fIII 309\/KEYNOTE\u2011775 trial. The combination of Eisai\u2019s oral multitargeted tyrosine\u2011kinase inhibitor lenvatinib and MSD\u2019s anti\u2011PD\u20111 antibody Pembrolizumab (Keytruda) demonstrated sustained overall survival (OS) benefits over conventional chemotherapy in patients with advanced endometrial carcinoma who had progressed after at least one platinum\u2011based regimen.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=44830\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eisai and Merck Present 5\u2011Year Survival Data for Lenvatinib\u2011Pembrolizumab in Advanced Endometrial Carcinoma at ESMO 2025\" \/>\n<meta property=\"og:description\" content=\"At the European Society for Medical Oncology (ESMO) 2025 Congress, Eisai (TYO: 4523) and Merck, Sharp &amp; Dohme Inc. (MSD; NYSE: MRK) unveiled compelling long\u2011term follow\u2011up data from the Phase\u202fIII 309\/KEYNOTE\u2011775 trial. The combination of Eisai\u2019s oral multitargeted tyrosine\u2011kinase inhibitor lenvatinib and MSD\u2019s anti\u2011PD\u20111 antibody Pembrolizumab (Keytruda) demonstrated sustained overall survival (OS) benefits over conventional chemotherapy in patients with advanced endometrial carcinoma who had progressed after at least one platinum\u2011based regimen.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=44830\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-28T07:32:53+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-28T07:32:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2806.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44830#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44830\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Eisai and Merck Present 5\u2011Year Survival Data for Lenvatinib\u2011Pembrolizumab in Advanced Endometrial Carcinoma at ESMO 2025\",\"datePublished\":\"2025-10-28T07:32:53+00:00\",\"dateModified\":\"2025-10-28T07:32:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44830\"},\"wordCount\":230,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44830#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2806.webp\",\"keywords\":[\"Academic conference\",\"Cancer\",\"Clinical trial results\",\"Combination therapy\",\"Eisai\",\"Merck Sharp &amp; Dohme\",\"MSD\",\"NYSE: MRK\",\"PD-1\\\/L1\",\"TKIs (EGFR VEGF BTK etc.)\",\"TYO: 4523\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=44830#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44830\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=44830\",\"name\":\"Eisai and Merck Present 5\u2011Year Survival Data for Lenvatinib\u2011Pembrolizumab in Advanced Endometrial Carcinoma at ESMO 2025 - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44830#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44830#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2806.webp\",\"datePublished\":\"2025-10-28T07:32:53+00:00\",\"dateModified\":\"2025-10-28T07:32:55+00:00\",\"description\":\"At the European Society for Medical Oncology (ESMO) 2025 Congress, Eisai (TYO: 4523) and Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK) unveiled compelling long\u2011term follow\u2011up data from the Phase\u202fIII 309\\\/KEYNOTE\u2011775 trial. The combination of Eisai\u2019s oral multitargeted tyrosine\u2011kinase inhibitor lenvatinib and MSD\u2019s anti\u2011PD\u20111 antibody Pembrolizumab (Keytruda) demonstrated sustained overall survival (OS) benefits over conventional chemotherapy in patients with advanced endometrial carcinoma who had progressed after at least one platinum\u2011based regimen.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44830#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=44830\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44830#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2806.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2806.webp\",\"width\":1080,\"height\":608,\"caption\":\"Eisai and Merck Present 5\u2011Year Survival Data for Lenvatinib\u2011Pembrolizumab in Advanced Endometrial Carcinoma at ESMO 2025\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44830#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eisai and Merck Present 5\u2011Year Survival Data for Lenvatinib\u2011Pembrolizumab in Advanced Endometrial Carcinoma at ESMO 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Eisai and Merck Present 5\u2011Year Survival Data for Lenvatinib\u2011Pembrolizumab in Advanced Endometrial Carcinoma at ESMO 2025 - Insight, China&#039;s Pharmaceutical Industry","description":"At the European Society for Medical Oncology (ESMO) 2025 Congress, Eisai (TYO: 4523) and Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK) unveiled compelling long\u2011term follow\u2011up data from the Phase\u202fIII 309\/KEYNOTE\u2011775 trial. The combination of Eisai\u2019s oral multitargeted tyrosine\u2011kinase inhibitor lenvatinib and MSD\u2019s anti\u2011PD\u20111 antibody Pembrolizumab (Keytruda) demonstrated sustained overall survival (OS) benefits over conventional chemotherapy in patients with advanced endometrial carcinoma who had progressed after at least one platinum\u2011based regimen.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=44830","og_locale":"en_US","og_type":"article","og_title":"Eisai and Merck Present 5\u2011Year Survival Data for Lenvatinib\u2011Pembrolizumab in Advanced Endometrial Carcinoma at ESMO 2025","og_description":"At the European Society for Medical Oncology (ESMO) 2025 Congress, Eisai (TYO: 4523) and Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK) unveiled compelling long\u2011term follow\u2011up data from the Phase\u202fIII 309\/KEYNOTE\u2011775 trial. The combination of Eisai\u2019s oral multitargeted tyrosine\u2011kinase inhibitor lenvatinib and MSD\u2019s anti\u2011PD\u20111 antibody Pembrolizumab (Keytruda) demonstrated sustained overall survival (OS) benefits over conventional chemotherapy in patients with advanced endometrial carcinoma who had progressed after at least one platinum\u2011based regimen.","og_url":"https:\/\/flcube.com\/?p=44830","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-10-28T07:32:53+00:00","article_modified_time":"2025-10-28T07:32:55+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2806.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=44830#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=44830"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Eisai and Merck Present 5\u2011Year Survival Data for Lenvatinib\u2011Pembrolizumab in Advanced Endometrial Carcinoma at ESMO 2025","datePublished":"2025-10-28T07:32:53+00:00","dateModified":"2025-10-28T07:32:55+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=44830"},"wordCount":230,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=44830#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2806.webp","keywords":["Academic conference","Cancer","Clinical trial results","Combination therapy","Eisai","Merck Sharp &amp; Dohme","MSD","NYSE: MRK","PD-1\/L1","TKIs (EGFR VEGF BTK etc.)","TYO: 4523"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=44830#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=44830","url":"https:\/\/flcube.com\/?p=44830","name":"Eisai and Merck Present 5\u2011Year Survival Data for Lenvatinib\u2011Pembrolizumab in Advanced Endometrial Carcinoma at ESMO 2025 - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=44830#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=44830#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2806.webp","datePublished":"2025-10-28T07:32:53+00:00","dateModified":"2025-10-28T07:32:55+00:00","description":"At the European Society for Medical Oncology (ESMO) 2025 Congress, Eisai (TYO: 4523) and Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK) unveiled compelling long\u2011term follow\u2011up data from the Phase\u202fIII 309\/KEYNOTE\u2011775 trial. The combination of Eisai\u2019s oral multitargeted tyrosine\u2011kinase inhibitor lenvatinib and MSD\u2019s anti\u2011PD\u20111 antibody Pembrolizumab (Keytruda) demonstrated sustained overall survival (OS) benefits over conventional chemotherapy in patients with advanced endometrial carcinoma who had progressed after at least one platinum\u2011based regimen.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=44830#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=44830"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=44830#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2806.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2806.webp","width":1080,"height":608,"caption":"Eisai and Merck Present 5\u2011Year Survival Data for Lenvatinib\u2011Pembrolizumab in Advanced Endometrial Carcinoma at ESMO 2025"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=44830#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Eisai and Merck Present 5\u2011Year Survival Data for Lenvatinib\u2011Pembrolizumab in Advanced Endometrial Carcinoma at ESMO 2025"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2806.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/44830","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=44830"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/44830\/revisions"}],"predecessor-version":[{"id":44845,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/44830\/revisions\/44845"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/44837"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=44830"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=44830"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=44830"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}